The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 18, 2025

Filed:

Jun. 06, 2025
Applicant:

Axsome Therapeutics, Inc., New York, NY (US);

Inventor:

Herriot Tabuteau, New York, NY (US);

Assignee:

Axsome Therapeutics, Inc., New York, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5415 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/4196 (2006.01); A61K 31/4439 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/40 (2006.01); A61K 47/69 (2017.01); A61P 25/06 (2006.01); C08B 37/16 (2006.01);
U.S. Cl.
CPC ...
A61K 47/02 (2013.01); A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 31/4196 (2013.01); A61K 31/4439 (2013.01); A61K 31/5415 (2013.01); A61K 45/06 (2013.01); A61K 47/40 (2013.01); A61K 47/6951 (2017.08); A61P 25/06 (2018.01); C08B 37/0012 (2013.01); C08B 37/0015 (2013.01);
Abstract

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tof meloxicam of 3 hours or less.


Find Patent Forward Citations

Loading…